{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2019-07-18T10%3A09%3A27.150Z&humanIndexable=true&max-ddpModified.=2019-07-18T16%3A44%3A01.641Z&tablingMemberConstituency=Gower&hansardHeading=Cannabis%3A+Medical+Treatments", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?max-ddpCreated=2019-07-18T10%3A09%3A27.150Z&humanIndexable=true&max-ddpModified.=2019-07-18T16%3A44%3A01.641Z&tablingMemberConstituency=Gower&hansardHeading=Cannabis%3A+Medical+Treatments", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2019-07-18T10%3A09%3A27.150Z&humanIndexable=true&max-ddpModified.=2019-07-18T16%3A44%3A01.641Z&tablingMemberConstituency=Gower&_metadata=all&hansardHeading=Cannabis%3A+Medical+Treatments", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&max-ddpCreated=2019-07-18T10%3A09%3A27.150Z&humanIndexable=true&max-ddpModified.=2019-07-18T16%3A44%3A01.641Z&tablingMemberConstituency=Gower&hansardHeading=Cannabis%3A+Medical+Treatments", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2019-07-18T10%3A09%3A27.150Z&humanIndexable=true&max-ddpModified.=2019-07-18T16%3A44%3A01.641Z&tablingMemberConstituency=Gower&hansardHeading=Cannabis%3A+Medical+Treatments", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2019-07-18T10%3A09%3A27.150Z&humanIndexable=true&max-ddpModified.=2019-07-18T16%3A44%3A01.641Z&tablingMemberConstituency=Gower&hansardHeading=Cannabis%3A+Medical+Treatments", "items" : [{"_about" : "http://data.parliament.uk/resources/1133166", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1133166/answer", "answerText" : {"_value" : "<p>In line with routine clinical practice patients wishing to seek a second opinion will be supported to do so. In the first instance clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then National Health Service trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support NHS trusts in identifying a suitable NHS specialist for a second opinion. Processes may differ in Scotland, Wales and Northern Ireland.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-06-27", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-06-27T12:42:09.417Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-06-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether patients whose prescription for a cannabis-based medical product is blocked by an NHS trust can appeal that decision.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"}
      }
      , "tablingMemberConstituency" : {"_value" : "Gower"}
      , "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"}
      ], "uin" : "266861"}
    , {"_about" : "http://data.parliament.uk/resources/1133167", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1133167/answer", "answerText" : {"_value" : "<p>The Department is in regular contact with the National Institute for Health and Care Excellence (NICE) and NHS England colleagues about a range of issues and has not met with drug manufacturers on funding of licensed cannabis-based products.<\/p><p>Sativex is currently the only licensed cannabis-based product available in the United Kingdom. NICE considered the clinical and cost effectiveness of Sativex in the development of its clinical guideline on the management of multiple sclerosis published in 2014. NICE was not able to recommend Sativex as a cost-effective use of NHS resources for the treatment of spasticity in people with multiple sclerosis. Sativex is not therefore routinely funded by the NHS in England for use in the treatment of multiple sclerosis, although clinicians are able to make a request for exceptional funding for individual patients who they think may benefit from treatment.<\/p><p>NICE has been asked to develop clinical guidelines on cannabis-based products for medicinal use and is expected to look at the clinical and cost effectiveness of treatments, including Sativex, as part of this work. This is expected to be published by October 2019.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-06-27", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-06-27T12:43:17.543Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-06-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with (a) NHS England, (b) drug manufacturers and (c) the National Institute for Health and Care Excellence on funding for licensed cannabis-based products.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"}
      }
      , "tablingMemberConstituency" : {"_value" : "Gower"}
      , "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"}
      ], "uin" : "266862"}
    , {"_about" : "http://data.parliament.uk/resources/1132764", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1132764/answer", "answerText" : {"_value" : "<p>The Government acted swiftly to change the law and those patients for whom it is clinically appropriate can be prescribed medicinal cannabis. It is a clinical decision whether to prescribe, and prescriptions of medicinal cannabis are available, and being issued where it is judged clinically appropriate for the patient.<\/p><p /><p />"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4070", "label" : {"_value" : "Biography information for Matt Hancock"}
        }
        , "answeringMemberConstituency" : {"_value" : "West Suffolk"}
        , "answeringMemberPrinted" : {"_value" : "Matt Hancock"}
        , "dateOfAnswer" : {"_value" : "2019-06-18", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-06-18T16:50:49.883Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-06-18", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "What progress the Government has made on making medical cannabis available to people who need it.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"}
      }
      , "tablingMemberConstituency" : {"_value" : "Gower"}
      , "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"}
      ], "uin" : "911421"}
    , {"_about" : "http://data.parliament.uk/resources/1037890", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1037890/answer", "answerText" : {"_value" : "<p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019.<\/p><p> <\/p><p>The Department has made no estimate of future demand for medical cannabis over the next 12 months.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-01-16", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "206442"}
        , {"_value" : "206443"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-01-16T15:13:41.753Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-01-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many NHS prescriptions have been issued for patients to use medical cannabis since 1 November 2018.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"}
      }
      , "tablingMemberConstituency" : {"_value" : "Gower"}
      , "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"}
      ], "uin" : "206441"}
    , {"_about" : "http://data.parliament.uk/resources/1037900", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1037900/answer", "answerText" : {"_value" : "<p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019.<\/p><p> <\/p><p>The Department has made no estimate of future demand for medical cannabis over the next 12 months.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-01-16", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "206441"}
        , {"_value" : "206443"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-01-16T15:13:41.817Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-01-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many NHS prescriptions for medicinal cannabis have been dispensed at a pharmacy since 1 November 2018.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"}
      }
      , "tablingMemberConstituency" : {"_value" : "Gower"}
      , "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"}
      ], "uin" : "206442"}
    , {"_about" : "http://data.parliament.uk/resources/1037901", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1037901/answer", "answerText" : {"_value" : "<p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019.<\/p><p> <\/p><p>The Department has made no estimate of future demand for medical cannabis over the next 12 months.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-01-16", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "206441"}
        , {"_value" : "206442"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-01-16T15:13:41.847Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-01-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of (a) prescriptions of and (b) patients who will use medical cannabis in the next 12 months.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"}
      }
      , "tablingMemberConstituency" : {"_value" : "Gower"}
      , "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"}
      ], "uin" : "206443"}
    , {"_about" : "http://data.parliament.uk/resources/1003743", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1003743/answer", "answerText" : {"_value" : "<p>The Government has rescheduled cannabis-based products for medicinal use from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations 2001. Doctors on the specialist register of the General Medical Council may now prescribe these products where there might be potential benefit to individual patients. General practitioners will not be able to prescribe but the Government has commissioned the National Institute for Health and Care Excellence to produce guidance for all clinicians by October 2019.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-20T11:38:40.057Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-09", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans he has to increase the (a) knowledge and (b) awareness among GPs of the benefits of medicinal cannabis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"}
      }
      , "tablingMemberConstituency" : {"_value" : "Gower"}
      , "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"}
      ], "uin" : "189815"}
    , {"_about" : "http://data.parliament.uk/resources/946807", "AnsweringBody" : [{"_value" : "Home Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/946807/answer", "answerText" : {"_value" : "<p>Following the short term ACMD advice, the Home Secretary has confirmed that cannabis-derived medicinal products will be rescheduled. This means that senior clinicians will be able to prescribe the medicines to patients with an exceptional clinical need.<\/p><p>The Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency will now develop a clear definition of what constitutes a cannabis-derived medicinal product. Only products meeting this definition will be rescheduled. Other forms of cannabis will be kept under strict controls and will not be available on prescription. We will provide more details about this definition and the kinds of products that will be covered in due course.<\/p><p>The Home Secretary has been clear that speed is of the essence and the products will be available on prescription in the autumn.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1561", "label" : {"_value" : "Biography information for Mr Nick Hurd"}
        }
        , "answeringMemberConstituency" : {"_value" : "Ruislip, Northwood and Pinner"}
        , "answeringMemberPrinted" : {"_value" : "Mr Nick Hurd"}
        , "dateOfAnswer" : {"_value" : "2018-09-07", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-09-07T18:35:25.347Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "1"}
      , "answeringDeptShortName" : {"_value" : "Home Office"}
      , "answeringDeptSortName" : {"_value" : "Home Office"}
      , "date" : {"_value" : "2018-07-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for the Home Department, with reference to the recommendation of the Advisory Council on the Misuse of Drugs that medicinal cannabis products be moved out of Schedule 1 and into Schedule 2 of the Misuse of Drugs Regulations, how long it will take to reclassify the medicinal cannabis oil used by Alfie Dingley and Billy Caldwell; and whether he plans to ensure that all patients who might benefit from such treatment will be able to access medicinal cannabis by the time the House returns from its summer recess.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"}
      }
      , "tablingMemberConstituency" : {"_value" : "Gower"}
      , "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"}
      ], "uin" : "167359"}
    , {"_about" : "http://data.parliament.uk/resources/943843", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/943843/answer", "answerText" : {"_value" : "<p>The Department is working with NHS England and equivalents in the devolved administrations to ensure that cannabis-based medicinal products are sourced and supplied where a licence is granted. In the longer-term, prescribing guidance will be developed following any decision to reschedule these products.<\/p><p> <\/p><p>Guidance on the licensing process for access to cannabis and cannabis-based medicinal products is available on the Home Office Gov.uk website.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-07-23", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-07-23T15:04:17.587Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-07-18", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions he is having with NHS England to ensure that consultants are aware of the licensing process for access to medical cannabis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"}
      }
      , "tablingMemberConstituency" : {"_value" : "Gower"}
      , "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"}
      ], "uin" : "165715"}
    , {"_about" : "http://data.parliament.uk/resources/942590", "AnsweringBody" : [{"_value" : "Northern Ireland Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/942590/answer", "answerText" : {"_value" : "<p>Northern Ireland Office officials are in regular contact with Department of Health Northern Ireland officials to ensure that, following a recommendation from the expert panel, appropriate licences are in place which allow patients to be treated with cannabis-based medicines.<\/p><p>It would not be appropriate for me to discuss the specific circumstances of certain individuals.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1496", "label" : {"_value" : "Biography information for Shailesh Vara"}
        }
        , "answeringMemberConstituency" : {"_value" : "North West Cambridgeshire"}
        , "answeringMemberPrinted" : {"_value" : "Mr Shailesh Vara"}
        , "dateOfAnswer" : {"_value" : "2018-07-23", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-07-23T08:49:05.83Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "21"}
      , "answeringDeptShortName" : {"_value" : "Northern Ireland"}
      , "answeringDeptSortName" : {"_value" : "Northern Ireland"}
      , "date" : {"_value" : "2018-07-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Northern Ireland, what discussion she has had with the Department of Health in Northern Ireland the conditions of the licence for Billy Caldwell to ensure the availability of medicinal cannabis without the need to travel to Belfast.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"}
      }
      , "tablingMemberConstituency" : {"_value" : "Gower"}
      , "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"}
      ], "uin" : "164518"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&max-ddpCreated=2019-07-18T10%3A09%3A27.150Z&humanIndexable=true&max-ddpModified.=2019-07-18T16%3A44%3A01.641Z&tablingMemberConstituency=Gower&hansardHeading=Cannabis%3A+Medical+Treatments", "page" : 0, "startIndex" : 1, "totalResults" : 14, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}